In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV

Diagnostic Microbiology and Infectious Disease

Volumn 47, Issue 4, 2003, Pages 587-593

  Garrison, Mark W ^a   Schimmels, Julie A ^a   Madaras Kelly, Karl J ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; MUTANT PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APPARATUS; ARTICLE; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA MODIFICATION; DRUG POTENCY; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 0346095191     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00152-4     Document Type: Article

References (24)

1. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
2. Chapin-Robertson, K., & Edberg, S. C. (1991). Measurement of antibiotics in human body fluids: techniques and significance. In: Antibiotics in Laboratory Medicine (3d ed.). Ed, V Lorian. Baltimore, MD. Williams and Wilkins, p 313.
3. Chen D.K., McGeer A., DeAzavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 341:1999;233-239.
4. Davies T.A., Kelly L.M., Pankuch G.A., Credito K.L., Jacobs M.R., Appelbaum P.C. Antipneumococcal activity of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother. 44:2000;302-310.
5. Fukuda H., Kishii R., Takei M., Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:2001;1649-1653.
6. Garrison M.W., Campbell D.M., Sclar D.A., Anderson D.E. Comparative activity of temafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae using an in vitro pharmacodynamic model apparatus. Clin Ther Res. 55:1994;1432-1441.
7. Garrison M.W., Malone C.L., Eiland J. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 40:1996;1545-1547.
8. Garrison M.W., Malone C.L., Eiland J., Anderson D.E. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis. 27:1997;139-145.
9. Heaton V.J., Ambler J.E., Fisher L.M. Potent anti-pneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vitro target preference for gyrase, and enhanced stabilization of cleavable complex in vitro. Antimicrob Agents Chemother. 44:2000;3112-3117.
10. Heffelfinger J.D., Dowell S.F., Jorgenson J.H., et al. Management of community-acquired pneumonia in an era of pneumococcal resistance a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group . Arch Intern Med. 160:2000;1399-1408.
11. Ho P.L., Que T.L., Tsang D.N.C., Ng T.K., Chow K.H., Seto W.H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 43:1999;1310-1313.
12. Hoban D.J., Bouchillon S.K., Karlowski J.A., Johnson J.L., Butler D.L., Miller L.A., Poupard J.A. A comparative in vitro surveillance study of gemifloxacin activities against 2632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. Antimicrob Agents Chemother. 44:2000;3008-3011.
13. Hooper D.C. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis. 27:(suppl 1):1998;54-63.
14. Jones M.E., Sahm D.F., Martin N., Scheuring S., Heisig P., Thornsberry C., Kohrer K., Schmitz F.J. Prevalence of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 44:2000;462-466.
15. Jorgensen J.H., Weigel L.M., Ferraro M.J., Swenson J.M., Tenover F.C. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in gyrA, parC, and pare loci. Antimicrob Agents Chemother. 43:1999;329-334.
16. Jorgensen J.H., Weigel L.M., Swenson J.M., Whitney C.G., Ferraro M.J., Tenover F.C. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 44:2000;2962-2968.
17. Koeth L.M., Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Appelbaum P.C. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-fluoroquinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. Int J Antimicrob Agents. 19:2002;33-37.
18. Lacy M.K., Lu W., Xu X., Tessier P.R., Nicolau D.P., Quintiliani R., Nightingale C.H. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 43:1999;672-677.
19. Lister P.D. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro model impact of area under the curve/MIC ratios on eradication . Antimicrob Agents Chemother. 46:2002;69-74.
20. National Committee for Clinical Laboratory Standards. (2002). Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. Wayne, PA: NCCLS Document MIOO-S12.
21. Pestova E., Millichap J.J., Noskin G.A., Peterson L.R. Intracellular targets of moxifloxacin a comparison with other fluoroquinolones . J Antimicrob Chemother. 45:2000;583-590.
22. Smith H.J., Nichol K.A., Hoban D.J., Zhanel G.G. Dual activity of fluoroquinolones against Streptococcus pneumoniae the facts behind the claims . J Antimicrob Chemother. 49:2002;893-895.
23. Weigel L.M., Anderson G.J., Facklam R.R., Tenover F.C. Genetic analysis of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:2001;3517-3523.
24. Zhanel G.G., Walters M., Laing N., Hoban D.J. In vitro pharmacodynamic modeling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 47:2001;435-440.